In 2006, close to 235,000 men will be diagnosed with prostate cancer and over 27,000 will die from the disease.1 Androgen ablative therapy is generally the treatment of choice for recurrent or metastatic prostate cancer. The immediate response is generally profound; however, in most cases disease will continue to progress within 20 months.2,3 Much progress has been made in recent years in the area of hormone-refractory prostate cancer (HRPC), and promising research has the potential to further improve outcomes for these patients. Historically, chemotherapy for HRPC was largely considered palliative, however several randomized clinical trials have demonstrated modest survival benefit with docetaxel-based chemotherapy.4 Multiple clinical trials are underway to explore advanced treatment options through the use of different systemic combinations and targeted therapies. This program will review the current guidelines in the treatment of HRPC and discuss emerging treatment options and ongoing clinical trials.
This educational series will provide the latest clinical trial information and treatment guidelines for the management of some of the more challenging and prevalent advanced cancer types, including head & neck, gastric, non-small-cell-lung, prostate, and breast cancer. This educational program is intended for community oncologists and oncology nurses in order to provide their patients with the best care available.
1. American Cancer Society. Cancer Facts and Figures 2006. Atlanta: American Cancer Society; 2006.
2. Sharifi N, Dahut WL, Steinberg SM et al. A retrospective study of the time to clinical endpoints for advanced prostate cancer (abstract). BJU Int 2005 November;96(7):985-9.
3. Winquist E, Waldron T, Berry S, Ernst DS, Hotte S, Lukka H. Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group. BMC Cancer 2006;6:112.
4. Berry W, Eisenberger M. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy. Oncologist 2005;10 Suppl 3:30-9.
Target Audience
This educational program is intended for community oncologists and oncology nurses.
Learning Objectives
At the conclusion of these activities participants should be able to:
- Review patient selection issues such as when and in whom to use chemotherapy in Hormone-Refractory Prostate Cancer (HRPC)
- Discuss the rationale for first-line treatment recommendations in HRPC, specifically looking at clinical trial results
- Explore emerging treatment options for HRPC that has progressed beyond first-line therapy
- Illustrate therapeutic decisions through a case presentation in the treatment of HRPC
The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Potomac Center for Medical Education designates this educational activity for a maximum of 1.25 AMA PRA Category I credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Physicians have the opportunity to earn up to 6.25 AMA PRA Category I credit(s)™ by completing this series.
Anthony J. Jannetti, Inc. (AJJ) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center (ANCC) Commission on Accreditation.
Educational design through the joint sponsorship of Anthony J. Jannetti, Inc. and Potomac Center for Medical Education.
Anthony J. Jannetti, Inc. designates this program for 1.25 CE contact hours. Participants should claim only those contact hours actually spent in the educational activity.
Dr. Charles James Ryan is a medical oncologist specializing in urologic cancer. His focus in patient care is therapy for hormone refractory prostate cancer, hormonal therapy and systemic therapies for patients with high-risk localized prostate cancer. His research addresses the development of treatments targeting the mechanisms of androgen independent prostate cancer progression, including secondary hormonal therapies, immune-based therapies and angiogenesis inhibitors. Ryan also has experience in pre-clinical tumor modeling and the evaluation of prostate cancer genomics studies. Ryan earned a medical degree at the University of Wisconsin, Madison, and completed a residency in internal medicine at the University of Wisconsin Hospital and Clinics, where he served as chief resident. He went on to complete a fellowship in oncology-hematology at Memorial Sloan-Kettering Cancer Center. He is an assistant clinical professor at UCSF.
Dr. William R. Berry is a North Carolina native, and attended Davidson College and Duke University School of Medicine. He did an internship and residency in internal medicine at Duke, and also completed a fellowship in hematology and oncology at Duke. He is board certified in internal medicine, hematology, and oncology. He established Raleigh Hematology Oncology Clinic in 1979 as a solo physician. This practice, now known as Cancer Centers of North Carolina, has grown to include 16 physicians including two radiation oncologists.
His primary clinical interest for the last 10 years has been the medical management of prostate cancer. He has served as chair or co-chair of the Genito-Urinary Research Committee of US Oncology since 1996. In that role he has been an investigator on numerous clinical trials in the management of prostate cancer, and has been an author on many peer review published articles.
Dr. Berry, ironically, was treated successfully for prostate cancer in 2002. Since that time he has served as medical advisor for his local prostate cancer support group, "Man to Man." He is married, and has 5 children. His hobbies include gardening, fly fishing, boating, and collecting wine.
William K. Oh, MD is an Assistant Professor of Medicine at the Harvard Medical School in Boston, Massachusetts. His teaching responsibilities extend from serving as preceptor and tutor to medical students, to teaching on rounds to house staff at Brigham and Women's Hospital, to mentoring medical oncology fellows at the Dana-Farber Cancer Institute, to giving talks to the local and national medical community. Dr. Oh also is Clinical Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute and Associate Physician at Brigham and Women's Hospital, both in Boston.
Dr. Oh earned his medical degree from New York University School of Medicine, New York, New York, in 1992. He completed his internship and residency in internal medicine at Brigham and Women's Hospital in Boston. Dr. Oh subsequently completed a fellowship in medical oncology at the Dana-Farber Cancer Institute in 1997.
Dr. Oh serves on the Cancer Education Committee of the American Society of Clinical Oncology (ASCO) and is a cadre member of the Genitourinary Committee of Cancer and Leukemia Group B (CALGB). Dr. Oh is an ad hoc reviewer for the Journal of Clinical Oncology, Journal of Urology, Clinical Cancer Research and Cancer. In addition, he co-edits the "Testicular Cancer" chapter for Up to Date and is on the editorial board of Clinical Prostate Cancer.
Dr. Oh has authored or co-authored >100 original articles, reviews and book chapters on topics including the management of advanced prostate cancer. Dr. Oh's research interests include the role of chemotherapy in both hormone-refractory (HRPC) and localized high-risk prostate cancer, the role of estrogens in the treatment of advanced prostate cancer, and the development of a prospective database of prostate cancer patients seen at the Dana-Farber Cancer Institute.
Potomac Center for Medical Education (PCME) adheres to guidelines of the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All faculty in a position to control the content of a continuing medical education program sponsored by the Potomac Center for Medical Education are required to disclose any relevant financial relationships with any commercial interest. All conflicts are identified and resolved by PCME in advance of delivery of the activity to learners.
Charles Ryan, MD
Speaker:
- Sanofi-Aventis
William Berry, MD
Speaker:
- Sanofi-Aventis
William K. Oh, MD
Consultant:
- Abbott
- Abraxis Oncology
- Berlex/Schering AG
- Dendreon
- Eyetech Technologies
- Genomic Health
- ImClone
- Novacea
- Roche
- Sanofi-Aventis
Speakers Bureau:
- Amgen
- AstraZeneca
- Eli Lilly
- Novartis
- Sanofi-Aventis
Grants/Research Support:
- Bristol-Myers Squibb
- Celgene
- Genentech
- Roche
- Sanofi-Aventis
back to top
